Purpose: The aim of the study was to evaluate the potential influence of ranibizumab and bevacizumab on platelet activation and aggregation, which are critical processes in the pathogenesis of arterial thromboembolic events (ATEs). Methods: For the assessment of platelet function, flow cytometry and aggregometry were employed. Platelets were isolated from healthy volunteers and exposed to ranibizumab (1 mg/ml and 150 ng/ml) and bevacizumab (2.5 mg/ml and 3 μg/ml) or their solvents for 10 and 30 min prior to the addition of TRAP (25 μM), PAR-4-AP (25 μM) or thrombin (0.02 U/ml). The surface expression of activated GP IIb/IIIa, P-selectin (CD62P) and platelet-bound stromal cell-derived factor-1 (SDF-1) was measured on resting (nonactivated) and activated platelets by flow cytometry. The platelet aggregation capacity was examined using light transmission aggregometry. Results: The expression of surface activation markers did not differ significantly between nonstimulated and TRAP-, PAR-4-AP- or thrombin-activated platelets after incubating with ranibizumab. However, GP IIb/IIIa, CD62P and SDF-1 were significantly downregulated in PAR-4-AP- and thrombin-activated platelets after exposure to bevacizumab 2.5 mg/ml. In addition, ranibizumab- and bevacizumab-FITC were significantly increased in all activated platelets. No significant differences were observed in the aggregation of activated platelets after incubation with ranibizumab or bevacizumab. Conclusion: All ranibizumab concentrations as well as the bevacizumab concentration of 3 μg/ml had no influence on platelet activation and aggregation. Therefore, this in vitro study did not show any relationship between the exposition of activated platelets to ranibizumab or bevacizumab and the development of ATEs. However, the highest level of bevacizumab interfered with platelet activation, leading to downregulation of platelet activation markers. This observation might explain why the systemic treatment with high-dose bevacizumab could be associated with an increased risk of bleeding. Regarding the use of lower intravitreal dosages, further research should focus on the complex interactions between platelets and other cells, such as endothelial cells, which might stronger relate to a potentially increased risk of ATEs and depend on systemic vascular endothelial growth factor levels. Facing the different activation profiles, the diverse effects of the drugs on the cellular level have to be critically scrutinized for their clinical relevance.

Keywords:
Bevacizumab, Ranibizumab, Platelet function, Arterial thromboembolic event, Thrombin
1.
Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, et al: Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-881.
2.
Klettner A, Roider J: Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008;49:4523-4527.
3.
Gaudreault J, Fei D, Rusit J Suboc P, Shiu V: Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733.
4.
Rouvas A, Liarakos VS, Theodossiadis P, Papathanassiou M, Petrou P, et al: The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica 2009;223:383-389.
5.
Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, et al: A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-1739.
6.
Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
7.
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, et al: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-185.
8.
Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK: Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011;22:1404-1412.
9.
Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, et al; Tübingen Bevacizumab Study Group: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823.
10.
Kim H, Robinson SB, Csaky KG: FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009;15:2803-2812.
11.
Sharma S, Johnson D, Abouammoh M, Hollands S, Brissette A: Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 2012;47:275-279.
12.
Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239.
13.
Ranpura V, Hapani S, Chuang J, Wu S: Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49:287-297.
14.
Meyer CH, Holz FG: Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) 2011;25:661-672.
15.
Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, et al: Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012;345:e4203.
16.
Mitchell P: A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 2011;27:1465-1475.
17.
Jennings LK: Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009;102:248-257.
18.
Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF: A platelet α-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880-886.
19.
Diacovo TG, Puri KD, Warnock RA, Springer TA, von Andrian UH: Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996;273:252-225.
20.
Stellos K, Kopf S, Paul A, Marquardt JU, Gawaz M, et al: Platelets in regeneration. Semin Thromb Hemost 2010;36:175-184.
21.
Li W, Wang J, Shen J, Zhang J, Lu L, Xu G: Comparison of pro-apoptotic effects of Avastin and Lucentis in rat primary neuronal cells. ARVO E-Abstract 2012;5318/A343.
22.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, et al: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182.
23.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
24.
Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, et al: Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807-4813.
25.
Thaler S1, Fiedorowicz M, Choragiewicz TJ, Bolz S, Tura A, et al: Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage. Acta Ophthalmol 2010;88:e170-e176.
26.
Stellos K, Langer H, Gnerlich S, Panagiota V, Paul A, et al: Junctional adhesion molecule A expressed on human CD34+ cells promotes adhesion on vascular wall and differentiation into endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2010;30:1127-1136.
27.
Stellos K, Langer H, Daub K, Schoenberger T, Gauss A, et al: Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008;117:206-215.
28.
Davi G, Patrono C: Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494.
29.
Fateh-Moghadam S, Htun P, Tomandl B, Sander D, Stellos K, et al: Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost 2007;97:974-978.
30.
Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P: Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol 2012;74:230-240.
31.
Wurster T, Stellos K, Haap M, Seizer P, Geisler T, et al: Platelet expression of stromal-cell-derived factor-1 (SDF-1): an indicator for ACS? Int J Cardiol 2013;164:111-115.
32.
Ranpura V, Hapani S, Chuang J, Wu S: Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49:287-297.
33.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al; MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
34.
Dafer RM, Schneck M, Friberg TR, Jay WM: Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007;22:201-204.
35.
Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, et al; ABC Trial Investigators: Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459.
36.
Lazic R, Gabric N: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185.
37.
Potter MJ, Claudio CC, Szabo SM: A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010;94:174-179.
38.
Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
39.
Lynch SS, Cheng CM: Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-625.
40.
Ziemssen F, Grisanti S, Bartz-Schmidt KU: The international intravitreal bevacizumab safety survey. Br J Ophthalmol 2006;90:1440-1441.
41.
Curtis LH, Hammill BG, Schulman KA, Cousins SW: Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-1279.
42.
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, et al: Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014;9:CD011230.
43.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Martin DF, Maguire MG, Fine SL, Grunwald JE, Fine SL, et al: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398.
44.
Sharma S, Johnson D, Abouammoh M, Hollands S, Brissette A: Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 2012;47:275-279.
45.
IVAN Study Investigators; Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-1411.
46.
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al: Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-1267.
47.
Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014;8:CD005139.
48.
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, et al: Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014;98:1636-1641.
49.
Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, et al: Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007;13:5341-5347.
50.
Wang W, Zhang X: Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. PLoS One 2014;9:e109744.
51.
Fehr M, Catschegn S, Reinhart WH, Madon J, Asmis L, et al: The influence of bevacizumab on platelet function. Swiss Med Wkly 2011;141:w13243
52.
Hang XF, Xu WS, Wang JX, Wang L, Xin HG, et al: Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011;67:613-23.
53.
Chong V, Kaiser PK, Mitchell P: Safety and efficacy of ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration. Eur Ophthalm Rev 2012;6:34-41.
54.
Massberg S, Enders G, Matos FC, Tomic LI, Leiderer R, et al: Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999;94:3829-3838.
55.
Chauhan AK, Goerge T, Schneider SW, Wagner DD: Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost 2007;5:583-589.
56.
Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, et al; Tübingen Bevacizumab Study Group: Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.